Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

Sponsor
Yongyi Zeng
Study ID
NCT06349317
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib — COMBINATION_PRODUCT
    1. Preoperative IMRT targeting PVTT and intrahepatic tumor lesions with a prescribed dose for 18Gy in 6 fractions delivered by using 6-MV X-rays with a linear accelerator at 5 fractions per week; 2. Perioperative combination of camrelizumab and apatinib Preoperatively, camrelizumab (200mg, every 2 weeks) combined with apatinib (250mg, daily) for 2 cycles (2 weeks as one cycle); Postoperatively, camrelizumab (200mg, every 3 weeks) combined with apatinib (250mg, daily) for 8 cycles (3 weeks as one cycle).

Study Details

This study is an open-label, single-arm prospective clinical trial that evaluates the efficacy and safety of neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib in the treatment of resectable hepatocellular carcinoma with portal vein tumor thrombus.

Key Dates

Start date
Apr 22, 2024
Status verified
Sep 2025
Primary completion
May 31, 2026
Completion
Jun 30, 2026

Study Design

Enrollment
33 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib
    Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib

Primary Outcome Measure

1-year Event-Free Survival (EFS) rate [ Time Frame: 1 year ]

Central Contacts

Related Studies